William Blair Predicts Incyte’s Q2 Earnings (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY) – Investment analysts at William Blair boosted their Q2 2025 earnings per share (EPS) estimates for Incyte in a report released on Tuesday, March 18th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $1.11 for the quarter, up from their prior forecast of $1.10. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.19 EPS and Q3 2026 earnings at $1.30 EPS.

Other research analysts also recently issued reports about the stock. Citigroup cut their price target on shares of Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a report on Tuesday, February 11th. Wells Fargo & Company boosted their target price on Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 19th. JMP Securities reaffirmed a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Finally, UBS Group began coverage on shares of Incyte in a research note on Tuesday, December 17th. They issued a “neutral” rating and a $77.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Incyte has a consensus rating of “Hold” and a consensus price target of $75.13.

Incyte Price Performance

INCY stock opened at $61.92 on Thursday. The firm has a 50 day moving average of $70.61 and a 200-day moving average of $70.11. The firm has a market capitalization of $11.98 billion, a P/E ratio of 229.34, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76. Incyte has a 12 month low of $50.35 and a 12 month high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last issued its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the sale, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Sheila A. Denton sold 599 shares of Incyte stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total value of $41,924.01. Following the sale, the executive vice president now owns 25,848 shares in the company, valued at $1,809,101.52. This represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,827 shares of company stock worth $3,322,618. 17.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Quintet Private Bank Europe S.A. bought a new position in Incyte in the 4th quarter worth about $26,000. Global X Japan Co. Ltd. grew its holdings in shares of Incyte by 144.7% in the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 230 shares during the period. R Squared Ltd purchased a new stake in Incyte during the fourth quarter valued at $30,000. Brooklyn Investment Group bought a new position in Incyte in the third quarter valued at about $30,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Incyte in the third quarter worth about $33,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.